Your account is not claimed yet. You can sign up with ORCID to claim your account.

Sandip Panicker

Years Active: 2014-2023
Publications (10 Years): 4

True North Therapeutics

University of California San Diego (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

True North Therapeutics

United States

Associate Director :: Inflammation

Education History

University of California San Diego

United States

PHD :: Neuroscience

Publications

Vaishnavi Rajagopal, Nina C Leksa, Ronald D Gorham, Siddharth Jindal, Soumya Vijayan Nair, Kevin E Knockenhauer, Joanne Chan, Tony S Byun, Courtney J Mercadante, Stephen James Moore, Sandip Panicker, Graham C Parry, Michael J Storek
SAR443809: A Selective Inhibitor of the Complement Alternative Pathway, Targeting Complement Factor Bb. Blood advances (2023)
Pavel A Nikitin, Eileen L Rose, Tony S Byun, Graham C Parry, Sandip Panicker
C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro. Journal of immunology (Baltimore, Md. : 1950) 202 (4) (2019)
Lisa A Lewis, Sandip Panicker, Rosane B DeOliveira, Graham C Parry, Sanjay Ram
Effect of a C1s Inhibitor on the Efficacy of Anti-Capsular Antibodies against Neisseria meningitidis and Streptococcus pneumoniae. ImmunoHorizons 3 (11) (2019)
Ulrich Jäger, Shirley D'Sa, Christian Schoergenhofer, Johann Bartko, Ulla Derhaschnig, Christian Sillaber, Petra Jilma-Stohlawetz, Michael Fillitz, Thomas Schenk, Gary Patou, Sandip Panicker, Graham C Parry, James C Gilbert, Bernd Jilma
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood 133 (9) (2018)
Ju Shi, Eileen L Rose, Andrew Singh, Sami Hussain, Nancy E Stagliano, Graham C Parry, Sandip Panicker
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 123 (26) (2014)

Sandip Panicker.css-eqlu8i{font-size:small;padding-left:4px;}